ArticleContrast media & molecular imaging2018
Thallium Labeled Citrate-Coated Prussian Blue Nanoparticles as Potential Imaging Agent.
Article in Contrast media & molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- In Vitro and In Vivo Radiotoxicity and Biodistribution of Thallium-201 Delivered to Cancer Cells by Prussian Blue Nanoparticles.ACS applied materials & interfaces · 2025Article
- Mechanisms of inclusion of thallium-201 into Prussian blue nanoparticles for nuclear medicine applications.Journal of materials chemistry. B · 2024Article
- Human Serum Albumin Protein Corona in Prussian Blue Nanoparticles.Nanomaterials (Basel, Switzerland) · 2024Article
- Rational nanoparticle design: Optimization using insights from experiments and mathematical models.Journal of controlled release : official journal of the Controlled Release Society · 2023Review
- Synthesis and preclinical application of a Prussian blue-based dual fluorescent and magnetic contrast agent (CA).PloS one · 2022Article
- [MnNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2021Article
- Fluorescent, Prussian Blue-Based Biocompatible Nanoparticle System for Multimodal Imaging Contrast.Nanomaterials (Basel, Switzerland) · 2020Article
- Large-scale synthesis of monodisperse Prussian blue nanoparticles for cancer theranostics via an "in situ modification" strategy.International journal of nanomedicine · 2019Article
- The influence of female mice age on biodistribution and biocompatibility of citrate-coated magnetic nanoparticles.International journal of nanomedicine · 2019Article
- Novel radiomics evaluation of bone formation utilizing multimodal (SPECT/X-ray CT) in vivo imaging.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The aim of this study was to develop and characterize a nanoparticle-based image-contrast platform which is biocompatible, chemically stable, and accessible for radiolabeling with Methods: The physical properties of citrate-coated Prussian blue nanoparticles (PBNPs) (iron(II);iron(III);octadecacyanide) doped with Results: PBNP accumulation peaked at 2 hours after injection predominantly in the kidneys and the liver followed by a gradual decrease in activity in later time points. Conclusion: We synthetized, characterized, and radiolabeled a Prussian blue-based nanoparticle platform for contrast material applications. Its in vivo radiochemical stability and biodistribution open up the way for further diagnostic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.